Company Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S.
aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N.
gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.
Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Country | Denmark |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Christian Kanstrup |
Contact Details
Address: Dr. Neergaards Vej, 5th Floor Horsholm, 2970 Denmark | |
| Phone | 45 31 31 97 53 |
| Website | evaxion-biotech.com |
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001828253 |
| CUSIP Number | 29970R105 |
| ISIN Number | US29970R2040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Kanstrup M.Sc. | Chief Executive Officer |
| Andreas Holm Mattsson | Co-Founder and Chief AI and Culture Officer |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
| Thomas Frederik Schmidt | Interim Chief Financial Officer |
| Dr. Jürgen Langhärig EMBA, Ph.D. | Head of Business Development and Member of Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | 6-K | Report of foreign issuer |
| Oct 9, 2024 | 6-K | Report of foreign issuer |
| Oct 4, 2024 | 6-K | Report of foreign issuer |